Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.0K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
Antimicrobial Proteins01:23

Antimicrobial Proteins

6.5K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telomere heterochromatin-mediated compartmentalization: Where ALT begins.

Trends in cell biology·2026
Same author

Using generative AI to transform peptide hits into small molecule leads.

Beilstein journal of organic chemistry·2026
Same author

Identification and characterization of WpDestabilase, a novel destabilase from the salivary glands of Whitmania pigra.

Protein expression and purification·2026
Same author

Diallyl trisulfide activates Nrf2 by promoting S-sulfhydration of Keap1 to attenuate acute hypobaric hypoxia-induced lung injury.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Transcriptomic analyses of labial glands and gut tissue from two wax moths, Achroia grisella and Galleria mellonella.

G3 (Bethesda, Md.)·2026
Same author

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer.

Journal of medicinal chemistry·2026
Same journal

In Silico ADMET: From Current Practices to Novel Profilers.

Journal of medicinal chemistry·2026
Same journal

A Zirconium Aza-BODIPY Derivative as a Near-Infrared Fluorescent/Photoacoustic Imaging Bimodal Probe.

Journal of medicinal chemistry·2026
Same journal

Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling.

Journal of medicinal chemistry·2026
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Potent Cyclic Peptide Inhibitors Disrupt the FANCM-RMI Interaction.

Lisa J Alcock1, Tianyi Gao1, Rohan Bythell-Douglas2

  • 1School of Chemistry, The University of Sydney, Camperdown, NSW 2145, Australia.

Journal of Medicinal Chemistry
|June 6, 2025
PubMed
Summary
This summary is machine-generated.

Researchers discovered the first chemical inhibitors targeting the FANCM-RMI protein interaction, crucial for genome stability in Alternative Lengthening of Telomeres (ALT) pathway cancers. These potent cyclic peptide inhibitors offer a new avenue for cancer therapy development.

More Related Videos

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.6K
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.6K
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

12.0K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • The FANCM-RMI protein-protein interaction is vital for maintaining genome stability.
  • This interaction is critical in cancers utilizing the Alternative Lengthening of Telomeres (ALT) pathway for survival.

Purpose of the Study:

  • To identify and characterize the first chemical inhibitors of the FANCM-RMI interaction.
  • To explore the potential of these inhibitors for developing new cancer therapies.

Main Methods:

  • Screening of cyclic peptides using mRNA display to identify inhibitors.
  • Characterization of inhibitor binding affinity (KD) and disruptive potency (IC50).
  • X-ray crystallography, alanine scanning, and co-immunoprecipitation studies to elucidate binding modes and in-cell activity.

Main Results:

  • Discovery of potent cyclic peptide inhibitors engaging the RMI1/2 binding pocket with nanomolar affinity (KD = 2-10 nM).
  • Inhibitors demonstrated significant disruption of the FANCM-RMI interaction (IC50 = 54-104 nM).
  • Structural studies revealed novel binding modes, and cell-based assays confirmed disruption of the native interaction.

Conclusions:

  • These cyclic peptides are the first validated inhibitors of the FANCM-RMI interaction.
  • They serve as valuable chemical tools for studying genome stability mechanisms.
  • They represent a promising starting point for developing therapeutics against ALT-driven cancers.